Overview

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation in Patients With Hematologic Malignancy

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate whether the combination of cyclophosphamide and abatacept versus the treatment used in standard of care will reduce the incidence of moderate and severe chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. GVHD occurs when the cells from your donor (the graft) see your body's cells (the host) as different and attack them.

Phase:

Phase 2

Details

Lead Sponsor:

Dimitrios Tzachanis, MD PhD

Collaborator:

Bristol-Myers Squibb

Treatments:

Abatacept
Calcineurin Inhibitors
Cyclophosphamide
Methotrexate
Tacrolimus